1. PRCA and Immunogenecity (Background)
   • PRCA and Immunogenecity
   
   
2. PRCA Patient Database Update
   • Patient Database Update
   • Dear Doctor: Important Update - Eprex (epoetin alfa) - Pure Red Cell Aplasia (PRCA, Erythroblastopenia)
   
   
3. CURRENT LITERATURE ON PRCA
   • European Best Practice Guidelines 9-13 Anaema Management
   • The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration ( i.v. or s.c. )
   • Human Response to Recombinant Human Proteins
   
   
4. Further Information
   • Further Information for Customers and Patients

  European Best Practice Guidelines 9-13 Anaema Management

"There is no difference in maintenance doses between i.v. and s.c. administration in haemodialysis patients at all dose levels."

Claude Jacobs, Walter Horl, Iain Macdougall, et al
European Best Practice Guidelines 9-13 Anaemia Management.
Nephrology Dialysis Transplantation (2000) 15 [Suppl 4]: 33-42.